.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Queensland Health
Medtronic
Federal Trade Commission
Novartis
Colorcon
Cerilliant
Merck
Mallinckrodt
Cantor Fitzgerald

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 070820

« Back to Dashboard

NDA 070820 describes DOPAMINE HYDROCHLORIDE, which is a drug marketed by Abbott, Abraxis Pharm, Baxter Hlthcare, Hospira, Igi Labs Inc, Intl Medication, Luitpold, Lyphomed, Smith And Nephew, Teligent, Teva Parenteral, Warner Chilcott, and B Braun, and is included in thirty-five NDAs. It is available from six suppliers. Additional details are available on the DOPAMINE HYDROCHLORIDE profile page.

The generic ingredient in DOPAMINE HYDROCHLORIDE is dopamine hydrochloride. There are nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the dopamine hydrochloride profile page.

Summary for 070820

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 070820

Ingredient-typeCatecholamines

Medical Subject Heading (MeSH) Categories for 070820

Suppliers and Packaging for NDA: 070820

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DOPAMINE HYDROCHLORIDE dopamine hydrochloride INJECTABLE;INJECTION 070820 ANDA American Regent, Inc. 0517-1905 0517-1905-25 25 VIAL, SINGLE-DOSE in 1 BOX (0517-1905-25) > 5 mL in 1 VIAL, SINGLE-DOSE
DOPAMINE HYDROCHLORIDE dopamine hydrochloride INJECTABLE;INJECTION 070820 ANDA Cardinal Health 55154-5708 55154-5708-8 1 VIAL, SINGLE-DOSE in 1 BAG (55154-5708-8) > 5 mL in 1 VIAL, SINGLE-DOSE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength80MG/ML
Approval Date:Feb 11, 1987TE:APRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Chinese Patent Office
Cerilliant
Johnson and Johnson
McKesson
Queensland Health
Express Scripts
Novartis
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot